deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03136406

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Sponsor: ImmunityBio, Inc.

Conditions Pancreatic Cancer
Interventions 5-Fluorouracil ALT-803 Capecitabine Cyclophosphamide ETBX-011 GI-4000 Leucovorin Oxaliplatin aNK for Infusion avelumab bevacizumab nab-paclitaxel
Updated 13 times since 2017 Last updated: May 13, 2024 Started: Aug 11, 2017 Primary completion: Nov 22, 2017 Completion: Nov 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

Other terminated trials from ImmunityBio, Inc.

More terminations from ImmunityBio, Inc.

Other Pancreatic Cancer trials with similar outcome

Browse all Pancreatic Cancer trials

Listed as NCT03136406, this PHASE1/PHASE2 trial focuses on Pancreatic Cancer and remains terminated or withdrawn. Sponsored by ImmunityBio, Inc., it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Sep 2020 · 23 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshot~Nov 2022 – ~May 2024 · 18 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Status: Active Not Recruiting → Terminated · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Unknown Status → Active Not Recruiting

  4. Nov 2022 — May 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Oct 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Oct 2018 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Nov 2017 — Jan 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ImmunityBio, Inc.
Data source: ImmunityBio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations